Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA-LPX ovarian cancer vaccine with neoadjuvant carboplatin/paclitaxel
NL-OMON46832Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of W-OVA1, carboplatin and paclitaxel in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Vaccine-specific immune response. Planned start Feb 2018; status: withdrawn.
02
Drugs
W-OVA1carboplatinpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON46832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46832.